IFM Investors Pty Ltd Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

IFM Investors Pty Ltd lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,996 shares of the medical research company’s stock after buying an additional 3,630 shares during the quarter. IFM Investors Pty Ltd’s holdings in Thermo Fisher Scientific were worth $14,568,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Sanders Morris Harris LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth $795,000. Mission Wealth Management LP grew its stake in Thermo Fisher Scientific by 3.6% during the 3rd quarter. Mission Wealth Management LP now owns 2,200 shares of the medical research company’s stock worth $971,000 after purchasing an additional 76 shares in the last quarter. Darwin Advisors LLC grew its stake in Thermo Fisher Scientific by 11.3% during the 3rd quarter. Darwin Advisors LLC now owns 638 shares of the medical research company’s stock worth $281,000 after purchasing an additional 65 shares in the last quarter. Roman Butler Fullerton & Co. acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth $213,000. Finally, Arden Trust Co grew its stake in Thermo Fisher Scientific by 6.3% during the 3rd quarter. Arden Trust Co now owns 3,702 shares of the medical research company’s stock worth $1,634,000 after purchasing an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 88.12% of the company’s stock.

Several research firms have recently issued reports on TMO. Argus upped their price objective on Thermo Fisher Scientific from $370.00 to $450.00 in a research report on Monday, July 27th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $460.00 to $480.00 and gave the stock an “overweight” rating in a research report on Monday, October 5th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Wednesday, July 15th. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $352.00 to $436.00 in a research report on Thursday, July 23rd. Finally, Atlantic Securities began coverage on Thermo Fisher Scientific in a research report on Wednesday, September 30th. They set an “overweight” rating and a $494.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $452.27.

In other news, Director Jim P. Manzi sold 3,218 shares of the stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $402.38, for a total transaction of $1,294,858.84. Following the completion of the transaction, the director now directly owns 21,803 shares of the company’s stock, valued at approximately $8,773,091.14. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Syed A. Jafry sold 20,513 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $414.94, for a total value of $8,511,664.22. Following the transaction, the vice president now directly owns 26,657 shares of the company’s stock, valued at $11,061,055.58. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,868 shares of company stock valued at $71,253,379. Company insiders own 0.44% of the company’s stock.

TMO traded up $4.03 on Friday, hitting $468.59. 1,070,263 shares of the company traded hands, compared to its average volume of 1,656,574. The company has a 50 day moving average of $433.77 and a 200-day moving average of $378.29. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $185.37 billion, a PE ratio of 50.71, a PEG ratio of 1.88 and a beta of 1.01. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $473.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.22. The firm had revenue of $6.92 billion during the quarter, compared to the consensus estimate of $6.91 billion. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. During the same period in the prior year, the business earned $3.04 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 15.27 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Further Reading: What is a Backdoor Roth IRA?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.